Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie IncfiledCriticalAbbvie Inc
Publication of DOP2012000266ApublicationCriticalpatent/DOP2012000266A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Peptides Or Proteins
(AREA)
Abstract
PROTEÍNAS DE UNIÓN AISLADAS, POR EJEMPLO, ANTICUERPOS O PORCIONES DE UNIÓN AL ANTÍGENO DE ÉSTOS, QUE SE UNEN AL FACTOR DE NECROSIS TUMORAL-ALFA (TNF-a), POR EJEMPLO, AL TNF-a HUMANO. COMPOSICIONES BASADAS EN ANTICUERPOS. MOLÉCULAS RELACIONADAS. COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN DICHOS ANTICUERPOS. MÉTODOS TERAPÉUTICOS Y DE DIAGNÓSTICO DONDE SE EMPLEAN DICHOS ANTICUERPOS.UNION PROTEINS ISOLATED, FOR EXAMPLE, ANTIBODIES OR PORTIONS OF UNION TO THE ANTIGEN OF THESE, THAT JOIN THE TUMOR-ALFA NECROSIS FACTOR (TNF-a), FOR EXAMPLE, TO HUMAN TNF-a. COMPOSITIONS BASED ON ANTIBODIES. RELATED MOLECULES. PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH ANTIBODIES. THERAPEUTIC AND DIAGNOSTIC METHODS WHERE SUCH ANTIBODIES ARE USED.
ANTIBODY OR FUNCTIONAL FRAGMENT THEREOF WHICH BINDS THE ACTIVE FORM OF HUMAN PLASMA KALLICREIN, PHARMACEUTICAL COMPOSITION AND METHOD OF DETECTION OF PLASMA KALLICREIN IN A PATIENT